Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.

Autor: Thiem VD; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Anh DD; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Ha VH; National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Viet Nam., Van Thom N; Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Viet Nam., Thang TC; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam., Mateus J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA., Carreño JM; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA., Raghunandan R; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA. Electronic address: rraghunandan@path.org., Huong NM; PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Viet Nam., Mercer LD; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Flores J; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Escarrega EA; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA., Raskin A; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA., Thai DH; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam., Van Be L; Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Viet Nam., Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA., Innis BL; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA., Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, USA. Electronic address: florian.krammer@mssm.edu., Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA; Department of Medicine, University of California, San Diego, (UCSD), La Jolla, CA, 92037, USA. Electronic address: daniela@lji.org.

Publikováno v: Vaccine [Vaccine] 2024 Nov 29; Vol. 44, pp. 126542. Date of Electronic Publication: 2024 Nov 29.